PAION AG
http://www.paion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PAION AG
Digital Health Roundup: VR, AI Trends In Rehabilitation; Cybersecurity Regulations; Medicare Updates
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights VR, AI and other high tech trends in rehabilitation and gait training. Hannah Daniel discusses cybersecurity updates such as the new NIST published draft for an updated version of the Cybersecurity Framework, a recent report by Health-ISAC, and an interview with MedCrypt’s Naomi Schwartz about the upcoming FDA cybersecurity regulations for premarket approvals.
ReWalk Robotics’ Planned Acquisition Of Anti-Gravity Maker AlterG For $19M Paves Way To Profitability
ReWalk Robotics’ planned $19m acquisition of AlterG will put ReWalk on the path to profitability and positive cash flow, creating a combined company with trailing 12-month revenues of about $26m.
Finance Watch: Turnstone Biologics Launches 14th Biopharma IPO Of 2023
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill
Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug for the firm – but upcoming Phase II data will need to be compelling.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- CeNeS Pharmaceuticals plc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice